CASI Pharmaceuticals advances in kidney transplant treatment and explores strategic sale in China
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a notable player in the biopharmaceutical sector, has made a significant announcement that could have wide-reaching implications for kidney transplant ... Read More
CASI Pharmaceuticals administers first FOLOTYN dose in China for PTCL treatment
In a significant stride toward addressing the critical medical needs of peripheral T-cell lymphoma (PTCL) patients in China, CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a trailblazer ... Read More